Transcriptional modulation of β-Secretase ameliorates amyloid pathology and cognitive deficits in Alzheimer’s disease models
Excessive amyloid‑β (Aβ) production, driven by β‑site APP cleaving enzyme‑1 (BACE1), is central to the pathogenesis of Alzheimer’s disease (AD), yet active‑site BACE1 inhibitors have failed in trials because of efficacy and safety limitations. Targeting BACE1 transcription offers an orthogonal strategy that may enable partial, context‑dependent suppression compatible with neuronal function. 1
Authors
- Dong‐Gyu Jo (ORCID: https://orcid.org/0000-0003-2271-1076)
- Seung Hyun Baek (ORCID: https://orcid.org/0000-0002-4863-5529)
- Han‐Gyu Bae (ORCID: https://orcid.org/0000-0001-7542-552X)
- Yoonsuk Cho (ORCID: https://orcid.org/0000-0002-6549-6436)
- Jinsu Park (ORCID: https://orcid.org/0000-0002-2040-5510)
Institutions
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026-09-29
- DOI
- https://doi.org/10.1038/s41392-026-02957-1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation of Korea